Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923207 · ClinicalTrials.gov registry record · Phase 1
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01923207 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 32 participants.
The verdict
NCT01923207, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.
Interventions
- DRUG Placebo
- DRUG DX-2930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-08-12 |
| Est. Completion | 2014-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923207
The ClinicalTrials.gov registry entry for NCT01923207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01923207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923207 about?
NCT01923207 is a clinical study titled "A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects". The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.
What is the current status of trial NCT01923207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-08-12. Estimated completion is 2014-01-07.
What interventions are being tested in trial NCT01923207?
The interventions under investigation include: Placebo (DRUG), DX-2930 (DRUG).
Who is sponsoring clinical trial NCT01923207?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.